Hikma Pharmaceuticals (LON:HIK) Price Target Lowered to GBX 2,400 at JPMorgan Chase & Co.

Hikma Pharmaceuticals (LON:HIK) had its price objective lowered by JPMorgan Chase & Co. from GBX 2,500 to GBX 2,400 in a report released on Friday morning, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities analysts have also weighed in on the stock. Berenberg Bank cut their price objective on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a research report on Thursday, October 16th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of GBX 2,416.

Hikma Pharmaceuticals Price Performance

Hikma Pharmaceuticals stock traded up GBX 60 during midday trading on Friday, reaching GBX 1,582. 1,155,675 shares of the company were exchanged, compared to its average volume of 1,297,659. The firm’s 50-day simple moving average is GBX 1,730.88 and its 200-day simple moving average is GBX 1,893.97. Hikma Pharmaceuticals has a 1 year low of GBX 1,522 and a 1 year high of GBX 2,360. The company has a market capitalization of £3.50 billion, a price-to-earnings ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insiders Place Their Bets

In other news, insider Laura Balan Balan acquired 3,500 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah bought 315,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150. Over the last 90 days, insiders have bought 332,500 shares of company stock valued at $533,130,500. Insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.